Insight Diagnostics Inc

Document Sample
Insight Diagnostics Inc Powered By Docstoc
					                             CONFIDENTIAL




insight Diagnostics, inc.

    Corporate Presentation
         September 2010
                                            CONFIDENTIAL


     insight Diagnostics, inc.

• FDA Approved Medical Device
• Offers Non-Invasive testing for the Diagnosis of
  Soft Tissue Injury
• Worker‟s Compensation & OSHA Compliant
                                      CONFIDENTIAL

Electrodiagnostic Functional
     Assessment (EFA)

   FDA Registered Class II Medical
   Device
   Patented & Dominant Intellectual
   Property
   EEOC, HHS and ADA Compliant
   Strong Legal Case History
                                             CONFIDENTIAL


              What is EFA?
Utilizing iDi‟s patented technology – the
Electrodiagnostic Functional Assessment(EFA), iDi
integrates five previously unrelated, AMA accepted
medical diagnostic procedures to assist doctors in the
assessment and aging of soft tissue injuries.
   • Surface EMG
  • Range of Motion
  • Functional Capacity Evaluation (FCE)
  • Pinch Strength
  • Grip Strength
                                            CONFIDENTIAL


               EFA Testing
• Defines precise injury site
• Accurately diagnoses and determines the
  approximate age of an injury, and determines the
  significance of disc pathology
• Determines if patient is compliant, malingering or in
  pain
• Is non-invasive and non-loading
• Result is a Comprehensive Medical Report by Board
  Certified Physicians
• Can provide site-specific treatment
  recommendations to assist the physician
                                             CONFIDENTIAL


The FDA Statement of Intended Use

 The EFA can distinguish between acute versus
 chronic pathology, approximate the age as well
 as the extent of an injury relative to the date of
 loss, objectively determine good vs. poor effort
 during testing, and identify patterns of referred
 pain with a non-invasive and non-loading test.
                                             CONFIDENTIAL

     Competitive Advantages vs.
      Current DiagnosticsTools
• Current diagnostic tools are subjective - “process of
  elimination”
• Diagnosis is dependent upon “subjective” complaints
• Current tools not designed to look at soft tissue
  injuries
• NCV (Nerve Conduction Velocity) and iEMG are
  designed to evaluate nerve and muscle status
• X-rays, MRIs and CT scans are not designed to be
  dynamic or to assess muscle functioning
                                         CONFIDENTIAL


 Competitive Advantages vs. Current
 Diagnostic Tools

• “MRI’s produce a 64% false positive;
• Myelograms 24%;
• Computed Tomographic scans 36%;
• Discograms 37%...
• …contributing to increasing rates of low
  back surgery”
            Jensen, Brant & Ross et al
            University of Pittsburgh
            NEJM Vol. 331„1997
                                                    CONFIDENTIAL

     Workers Compensation
• Soft Tissue injury represents a $60 Billion expense to
Payers - Insurance Companies & Corporations
   • According to a study by Travelers Insurance, Insight
   Diagnostics‟ EFA-EMG reduces health care expenditures by
   25% and returns injured workers to work 62 days sooner than
   current diagnostics, and has changed case law from the
   Federal court level to local jurisdictions.
• For worker‟s compensation claims, the EFA can
distinguish between acute versus chronic pathology,
approximate the age as well as the extent of an injury
relative to the date of loss, objectively determine good
vs. poor effort during testing, and identify patterns of
referred pain with a non-invasive and non-loading test.
                         CONFIDENTIAL


    Additional Markets
Sports Medicine
Neurology
  -Multiple Sclerosis
  -Migraines
Veterinary Medicine
Dentistry
                                        CONFIDENTIAL

        Case Studies
Geressy v Digital Equipment Corp
  Reversed $5.3M Product Liability Award
Lankford Construction
  Reduced WC Costs from $1.6M to
  $3,200
Travelers Study
  Average Claim Reduction of $10,000 (25%)
    Returned to Work 62 Days Sooner
                                                      CONFIDENTIAL


      Senior Management
Matthew E. Colpoys, CEO
     - 25 years experience in bio-medical industry.
     - Part of the early commercial group at Genentech,
     - Built commercial operations from the ground up at:
              - Pharmacia Peptide Hormones (Now Pfizer),
              - Neurex (Now Elan),
             - Insmed
MaryRose Cusimano-Reaston, PhD, President
     - Founder of Insight Diagnostics Inc,
     - Inventor and visionary behind the EFA
     - Holds three US patents; two patents pending, and three
       FDA registrations.
CONFIDENTIAL
                                       CONFIDENTIAL


              Conclusion
• EFA utilization can help employers and
  their insurance companies lower their
  expenses, ensure better care for their
  employees, and increase overall
  productivity by getting them back to work
  sooner and close claims faster.

• Multiple follow-on revenue opportunities.